Pro-Dex (NASDAQ:PDEX) Upgraded to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Pro-Dex (NASDAQ:PDEX) from a buy rating to a strong-buy rating in a report released on Monday.

Pro-Dex Trading Up 4.5 %

Shares of PDEX opened at $18.70 on Monday. The firm’s fifty day moving average is $17.87 and its two-hundred day moving average is $18.10. The stock has a market cap of $63.94 million, a PE ratio of 32.24 and a beta of 0.55. The company has a quick ratio of 2.08, a current ratio of 3.45 and a debt-to-equity ratio of 0.25. Pro-Dex has a 52-week low of $14.51 and a 52-week high of $22.99.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.14 earnings per share for the quarter. Pro-Dex had a net margin of 4.13% and a return on equity of 6.50%. The firm had revenue of $12.59 million for the quarter.

Institutional Investors Weigh In On Pro-Dex

An institutional investor recently raised its position in Pro-Dex stock. Punch & Associates Investment Management Inc. raised its stake in Pro-Dex, Inc. (NASDAQ:PDEX) by 8.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 69,610 shares of the medical instruments supplier’s stock after buying an additional 5,235 shares during the quarter. Punch & Associates Investment Management Inc. owned approximately 1.96% of Pro-Dex worth $1,093,000 at the end of the most recent quarter. 15.28% of the stock is currently owned by hedge funds and other institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.